December 16, 2019
Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with Duchenne Muscular Dystrophy (DMD). Read the Press Release
Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with Duchenne Muscular Dystrophy (DMD). Read the Press Release
Biophytis to attend Biotech Showcase™ 2020 in San Francisco, USA. Read the Press Release
Biophytis Presents Preliminary Analysis of SARA-OBS study at the 12th Annual Congress of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) in Berlin, Germany. Read the Press Release
Biophytis to attend 11th Geneva MidCap Event. Read the Press Release
Biophytis to participate in the 6th China Healthcare Summit organized by BioCentury and BayHelix in Shanghai. Read the Press Release
Biophytis Files IND Application with FDA for Sarconeos (BIO101) to Support Planned MYODA Clinical Program in Patients with DMD. Read the Press Release
Biophytis to attend BIO-Europe® in Hamburg. Read the Press Release
Biophytis Files Protocol Amendment to Optimize the SARA-INT Phase 2b Clinical Trial for Sarcopenia. Read the Press Release
Biophytis Reports H1 2019 Financial Results and Provides Business Update. Read the Press Release
Biophytis to attend The Galien MedStartUp 2019 Event in New York. Read the Press Release